Skip to main content

AxCell Licenses ProChart Data to NCI for Prostate Cancer Research

NEW YORK, June 18 - AxCell Biosciences said today it will give the National Cancer Institute access to part of its ProChart database to help it research a prostate cancer-suppressor gene.


The deal, announced in a Letter of Intent, calls for the NCI to give AxCell certain biological and biochemical data about the oncogene, which encodes for a protein containing an SH3 domain-binding ligand. In exchange, AxCell, a unit of biotech firm Cytogen, will give the NCI SH3 domain-interaction data from its ProChart tool.


Click here for more information.